Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Neuroscience Center, Samsung Medical Center, Seoul, South Korea.
Front Cell Infect Microbiol. 2022 Jul 5;12:858724. doi: 10.3389/fcimb.2022.858724. eCollection 2022.
An elevated adenosine deaminase (ADA) level in the cerebrospinal fluid (CSF) is considered a reliable marker of tuberculous meningitis (TBM). However, CSF-ADA levels can also be elevated in other diseases. We aimed to find the most common diagnosis of patients with elevated CSF-ADA levels for the last 10 years.
We retrospectively investigated the diagnoses of all patients with elevated CSF-ADA (ADA ≥ 10 IU/L) levels between 2010 and 2019 at the Samsung Medical Center. Definite TBM was defined based on microbiological evidence. Clinical TBM was defined based on the brain imaging and response to the standard TB treatment. We compared the laboratory characteristics of the three most common diagnoses.
CSF-ADA levels were elevated in 137 (5.6%) of 2,600 patients. The most common diagnoses included hematologic malignancy (HM; n = 36, 26.2%), TBM (n = 26, 19.0%), and viral meningitis (VM; n = 25, 18.2%). CSF-ADA levels did not differ significantly between TBM [median (interquartile range (IQR)), 20.2 IU/L (13.8-29.3)] and HM [16.5 (12.8-24.0)]. However, CSF-ADA levels were lower in VM [14.0 (11.0-16.1)] than in TBM (p = 0.027). Lymphocyte-dominant pleocytosis was more common in VM [77.0% (70.8-81.5)] than in TBM [16.0 (3.0-51.0), p = 0.015] or HM [36.0 (10.0-72.0); p = 0.032]. Interestingly, the CSF characteristics of clinical TBM were similar to those of VM but not definite TBM.
The most common diagnoses with elevated CSF-ADA levels were HM, followed by TBM and VM. Clinicians should carefully consider the differential diagnoses in patients with elevated CSF-ADA levels, especially those in the early stage of meningitis without microbiological evidence for TBM.
脑脊液(CSF)中腺苷脱氨酶(ADA)水平升高被认为是结核性脑膜炎(TBM)的可靠标志物。然而,CSF-ADA 水平也可能在其他疾病中升高。我们旨在寻找过去 10 年来 CSF-ADA 升高患者最常见的诊断。
我们回顾性调查了 2010 年至 2019 年期间在三星医疗中心 CSF-ADA(ADA≥10IU/L)升高的所有患者的诊断。明确的 TBM 是基于微生物学证据定义的。临床 TBM 是基于脑影像学和对标准 TB 治疗的反应来定义的。我们比较了三种最常见诊断的实验室特征。
在 2600 名患者中,有 137 名(5.6%)CSF-ADA 水平升高。最常见的诊断包括血液恶性肿瘤(HM;n=36,26.2%)、TBM(n=26,19.0%)和病毒性脑膜炎(VM;n=25,18.2%)。TBM(中位数(四分位距(IQR)),20.2IU/L(13.8-29.3)和 HM [16.5(12.8-24.0)之间的 CSF-ADA 水平没有显著差异。然而,VM 中的 CSF-ADA 水平[14.0(11.0-16.1)]低于 TBM(p=0.027)。淋巴细胞为主的白细胞增多症在 VM 中更为常见[77.0%(70.8-81.5)],而在 TBM 中则更为少见[16.0(3.0-51.0),p=0.015]或 HM [36.0(10.0-72.0);p=0.032]。有趣的是,临床 TBM 的 CSF 特征与 VM 相似,但与明确的 TBM 不同。
CSF-ADA 升高患者最常见的诊断是 HM,其次是 TBM 和 VM。临床医生应仔细考虑 CSF-ADA 升高患者的鉴别诊断,特别是在没有 TBM 微生物学证据的脑膜炎早期。